Escalation and De-escalation of Temporary Mechanical Circulatory Support: Joint Consensus Report of the PeriOperative Quality Initiative and the Enhanced Recovery After Surgery Cardiac Society
- PMID: 40187586
- DOI: 10.1016/j.athoracsur.2025.01.038
Escalation and De-escalation of Temporary Mechanical Circulatory Support: Joint Consensus Report of the PeriOperative Quality Initiative and the Enhanced Recovery After Surgery Cardiac Society
Abstract
Background: Temporary mechanical circulatory support (tMCS) for cardiogenic shock (CS) is increasing despite knowledge gaps and variations in management practices. This document was created to provide clinicians with guidance regarding initiation, escalation, and de-escalation of tMCS in patients with CS.
Methods: An interdisciplinary, international expert panel using a structured literature appraisal and modified Delphi method derived consensus statements regarding triggers for prompt patient assessment and initiating tMCS in CS, assessing adequacy of support, readiness for tMCS weaning, and next steps in nonrecovery. Individual statements were graded on the basis of the quality of available evidence.
Results: The panel addressed 4 main questions aimed at initiation, escalation, and de-escalation of tMCS. On the basis of available literature review and expert consensus, 11 recommendations were formulated. Key principles included recognition of the need for patients with CS who have ongoing hemodynamic compromise, tissue hypoperfusion, and metabolic derangements to be considered for early tMCS initiation. An interdisciplinary shock team should be involved in management, with early referral when patient conditions require care beyond center capabilities. Discussions providing anticipatory guidance should be performed with patients and decision makers before initiating tMCS. Management of tMCS involves frequent, timely hemodynamic and tissue perfusion reassessments to determine the need for escalation or weaning. For patients unable to be weaned from tMCS, evaluation should include interdisciplinary assessment for advanced therapies, with palliation included as a consideration in care discussions.
Conclusions: A practical guide to initiation, escalation, and de-escalation of tMCS is provided. Center-specific approaches that are based on local capabilities should be implemented.
Copyright © 2025 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosures Lauren M. Barron reports a relationship with Abiomed that includes: speaking and lecture fees. Roberto Lorusso reports a relationship with Xenios that includes: consulting or advisory; and with Abiomed that includes: speaking and lecture fees. Scott C. Silvestry reports a relationship with Abiomed that includes: consulting or advisory; with Abbott Vascular that includes: consulting or advisory; and with Medtronic that includes: consulting or advisory. Michael Z. Tong reports a relationship with Abiomed that includes: consulting or advisory; with Abbott Vascular that includes: consulting or advisory; and with LifeNet Health that includes: consulting or advisory. Daniel T. Engelman reports a relationship with Edwards Lifesciences that includes: consulting or advisory; with Renibus Therapeutics that includes: consulting or advisory; with Alexion Pharmaceuticals that includes: consulting or advisory; with Medela AG that includes: consulting or advisory; with Arthrex that includes: consulting or advisory; with AtriCure that includes: consulting or advisory; and with Pharmacosmos AS that includes: consulting or advisory. Andrew D. Shaw reports a relationship with Alexion Pharmaceuticals that includes: consulting or advisory; with Chugai Pharmaceutical Co that includes: consulting or advisory; with Alexion Pharmaceuticals includes: consulting or advisory; with Retia Medical that includes: consulting or advisory; with Renibus Therapeutics that includes: consulting or advisory; with Novartis Pharmaceuticals that includes: consulting or advisory; with RenalGuard Solutions that includes: consulting or advisory; and with Fresenius Medical Care that includes: consulting or advisory. Subhasis Chatterjee reports a relationship with Edwards Lifesciences that includes: consulting or advisory; with La Jolla Pharmaceutical Company that includes: consulting or advisory; with Eagle Pharmaceutical that includes: consulting or advisory; and with Baxter Pharmaceutical Products that includes: consulting or advisory. All other authors declare that they have no conflicts of interest.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical